Irosustat
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Irosustat
- Molecular weight
- 309.34
- Structure (SMILES)
- NS(=O)(=O)Oc1ccc2c3c(c(=O)oc2c1)CCCCC3
- 667 coumate
- 667 COUMATE
- 667-COUMATE
- bn 83495
- BN 83495
- BN-83495
- bn83495
- BN83495
- BN83495 (Cohort 1)
- BN83495 (Cohort 2)
- BN83495 (Cohort 3)
- irosustat
- Irosustat
- Irosustat (BN83495)
- irosustat [INN]
- IROSUSTAT [USAN]
- Irosustat [WHO-DD]
- irosustat inn
- irosustat usan
- irosustat who dd
- stx 64
- STX 64
- STX-64
- stx64
- STX64
And 2 more, listed on the interactive page.
- CAS registry numbers
- 288628-05-7
- ChEMBL ID
- CHEMBL286738
- InChIKey
- DSLPMJSGSBLWRE-UHFFFAOYSA-N
- PubChem compound IDs
- 5287541
- FDA ingredient codes (UNII)
- 366037O6O7
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -stat
Mechanisms of action
- Mechanism
- Steryl-sulfatase inhibitor
- Action type
- Inhibitor
- Target
- Steryl-sulfatase
- Protein identifier
- P08842
Open Targets mechanisms
- Mechanism
- Steryl-sulfatase inhibitor
- Action type
- Inhibitor
- Target
- Steryl-sulfatase
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0011962
- Subject identifier
- D016889
- Condition identifier
- EFO_0003869
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002447
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011962
- Highest recorded phase
- 2
- NCT00790374
- NCT00910091
- NCT01251354
- NCT01230970
- NCT01785992
- NCT01840488
- NCT01662726
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 99.6
- Calculated partition coefficient (ALogP)
- 1.64
- Calculated partition coefficient (XLogP)
- 2.3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 21
- Molecular formula
- C14H15NO5S
- Monoisotopic mass
- 309.06709375
- Natural product
- Yes
- Recorded assays
- 146
- Active assays
- 67
- Confirmatory
- Other
Related records
Trials (87)
- A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
- A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects
- A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects
- A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
- A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
- A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function
- A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
- A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
- A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
- A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
- A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis
- A Study of AV0328 Administered to Healthy Adult Volunteers
- A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma
- A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
- A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
- A Study of M701 (EpCAM and CD3) in Malignant Ascites
- A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
- A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
- A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.
In development for (4)
- Breast cancer Phase 2
- Breast neoplasm Phase 2
- Endometrial cancer Phase 2
- Prostate cancer Phase 1
Targets (1)
- STS Steryl-sulfatase inhibitor